[Cell Therapy Using Peripheral Mononuclear Cells Preconditioned by Oxygen-Glucose Deprivation for Ischemic Stroke]

Area of Science:

• Neuroscience
• Regenerative Medicine
• Cell Therapy

Background:

• Cerebral ischemia, or stroke, remains a leading cause of disability and death.
• Current cell therapies for cerebral ischemia often use challenging-to-obtain cells like embryonic stem cells or induced pluripotent stem cells.
• These existing therapies require complex preparation, limiting clinical application.

Purpose of the Study:

• To review the therapeutic potential of peripheral blood mononuclear cells (PBMCs) for treating cerebral ischemia.
• To highlight the benefits of preconditioning PBMCs using oxygen-glucose deprivation (OGD) for enhanced efficacy.
• To propose OGD-PBMCs as a simplified and effective cell therapy strategy for ischemic stroke.

Main Methods:

• Review of existing literature on cell therapies for cerebral ischemia.
• Focus on the isolation and preconditioning of peripheral blood mononuclear cells (PBMCs).
• Analysis of the therapeutic effects of oxygen-glucose deprivation preconditioned PBMCs (OGD-PBMCs) in preclinical models of cerebral ischemia.

Main Results:

• Peripheral blood mononuclear cells (PBMCs) are readily accessible and easier to collect compared to other stem cell sources.
• Oxygen-glucose deprivation (OGD) preconditioning enhances the therapeutic properties of PBMCs.
• OGD-PBMCs demonstrate significant therapeutic effects in models of cerebral ischemia, suggesting potential for stroke treatment.

Conclusions:

• Peripheral blood mononuclear cells (PBMCs) represent a viable and accessible cell source for cerebral ischemia therapy.
• Oxygen-glucose deprivation (OGD) preconditioning offers a straightforward method to improve PBMC therapeutic potential.
• OGD-PBMCs present a promising, simplified therapeutic strategy for managing ischemic stroke.